UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 78

Sortiert nach

Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

Antimicrobial Agents and Chemotherapy, 2010-10, Vol.54 (10), p.4137-4142

2010

Link zum Volltext

Verfügbarkeit prüfen

Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody

The Journal of infectious diseases, 2010-05, Vol.201 (10), p.1481-1487

2010

Link zum Volltext

Verfügbarkeit prüfen

Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab

Journal of translational autoimmunity (Online), 2021-01, Vol.4, p.100097, Article 100097

2021

Link zum Volltext

Verfügbarkeit prüfen

Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab

Journal of translational autoimmunity (Online), 2021-01, Vol.4, p.100083-100083, Article 100083

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding

Antimicrobial Agents and Chemotherapy, 2002-09, Vol.46 (9), p.2969-2976

2002

Link zum Volltext

Verfügbarkeit prüfen

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

AIDS (London), 2003-03, Vol.17 (5), p.691-698

2003

Link zum Volltext

Verfügbarkeit prüfen

T-1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide-Containing Treatment Regimen

The Journal of infectious diseases, 2005-04, Vol.191 (7), p.1155-1163

2005

Link zum Volltext

Verfügbarkeit prüfen

Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV

AIDS (London), 2023-06, Vol.37 (7), p.1057

2023

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine

The Journal of infectious diseases, 2015-07, Vol.212 (1), p.18-27

2015

Link zum Volltext

Verfügbarkeit prüfen

Loss of Cytomegalovirus-Specific CD4+ T Cell Responses in Human Immunodeficiency Virus Type 1–Infected Patients with High CD4+ T Cell Counts and Recurrent Retinitis

The Journal of infectious diseases, 2001-04, Vol.183 (8), p.1285-1289

2001

Link zum Volltext

Verfügbarkeit prüfen

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

The New England journal of medicine, 2003-05, Vol.348 (22), p.2175-2185

2003

Link zum Volltext

Verfügbarkeit prüfen

On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir

Liver international, 2016-11, Vol.36 (11), p.1611-1618

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial

Antiviral therapy, 2017-01, Vol.22 (3), p.215-223

2017

Link zum Volltext

Verfügbarkeit prüfen

Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006

Journal of antimicrobial chemotherapy, 2007-07, Vol.60 (1), p.170-174

2007

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults

Antiviral therapy, 2010-01, Vol.15 (5), p.711-720

2010

Link zum Volltext

Verfügbarkeit prüfen

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults

AIDS research and human retroviruses, 2002-07, Vol.18 (10), p.685-693

2002

Link zum Volltext

Verfügbarkeit prüfen

Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Persons with AIDS

The New England journal of medicine, 1996-06, Vol.334 (23), p.1491-1497

1996

Link zum Volltext

Verfügbarkeit prüfen

Oral Ganciclovir as Maintenance Treatment for Cytomegalovirus Retinitis in Patients with AIDS

The New England journal of medicine, 1995-09, Vol.333 (10), p.615-620

1995

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

The Journal of infectious diseases, 2013-03, Vol.207 (5), p.740-748

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(77)
Berichte
(1)

Sprache

Englisch
(78)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(62)
Science & Technology
(62)
Humans
(58)
Male
(45)
Adult
(42)
Female
(41)
Infectious Diseases
(38)
Biological And Medical Sciences
(35)
Hiv Infections - Drug Therapy
(35)
Medical Sciences
(33)
Immunology
(32)
Middle Aged
(32)
Virology
(26)
Aids/hiv
(23)
Microbiology
(22)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(21)
Antiviral Agents
(21)
Pharmacology. Drug Treatments
(21)
Human Immunodeficiency Virus
(20)
Hiv
(19)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species

Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody

Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab

Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial

Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

T-1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide-Containing Treatment Regimen

Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV

Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study

Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine

Loss of Cytomegalovirus-Specific CD4+ T Cell Responses in Human Immunodeficiency Virus Type 1–Infected Patients with High CD4+ T Cell Counts and Recurrent Retinitis

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial

Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006

Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults

Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Persons with AIDS

Oral Ganciclovir as Maintenance Treatment for Cytomegalovirus Retinitis in Patients with AIDS

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

Suchergebnisse filtern